New cancer clinical trial: Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease

Published on: January 28, 2019 at 12:00PM
Conditions:   Breast Cancer;   Triple Negative Breast Neoplasms
Interventions:   Drug: Nivolumab;   Drug: Ipilimumab;   Drug: Capecitabine
Sponsor:   Centre Leon Berard
Not yet recruiting
http://bit.ly/2Wqre5c